Niacin/simvastatin

Niacin/simvastatin
Combination of


Niacin	Vitamin
Simvastatin	Statin
Clinical data
Pregnancy category	US: X (Contraindicated)
Routes of administration	Oral
Legal status
Legal status	US: ℞-only
(verify)

Niacin/simvastatin (trade name Simcor, by Abbott) is a combination drug consisting of an extended release form of the vitamin niacin and the statin drug simvastatin. It is used for the treatment of dyslipidemia. It was approved by the FDA on February 15, 2008.^[1] On April 15, 2016, the FDA pulled the approval of niacin and fibrates used in combination with statin drugs, citing growing evidence that the benefits of combining niacin or fibrate drugs with statin drugs to not outweigh the risks, compared to statin therapy alone.

References

↑ "Drugs.com, Abbott Receives FDA Approval for Simcor (Niaspan / simvastatin), a Novel Combination Medicine for Comprehensive Cholesterol Management". Retrieved 2008-03-15.

Lipid modifying agents (C10)

GI tract

Cholesterol absorption inhibitors, NPC1L1	Ezetimibe SCH-48461

Bile acid sequestrants/resins (LDL)	Cholestyramine Colestipol Colestilan Colextran Colesevelam

Liver

Statins (HMG-CoA reductase, LDL)	Simvastatin^# Atorvastatin Fluvastatin Lovastatin Mevastatin Pitavastatin Pravastatin Rosuvastatin Cerivastatin^‡

Niacin and derivatives (HDL and LDL)	Niceritrol Niacin Nicofuranose Aluminium nicotinate Nicotinyl alcohol Acipimox

MTTP inhibitors (VLDL)	Dirlotapide Lomitapide Mitratapide

Blood vessels

Fibrates (PPAR)	Clofibrate^‡ Bezafibrate Aluminium clofibrate Gemfibrozil Fenofibrate Simfibrate Ronifibrate Ciprofibrate Etofibrate Clofibride Clinofibrate

CETP inhibitors (HDL)	Anacetrapib^† Dalcetrapib^§ Evacetrapib^§ Torcetrapib^§

Combinations

Other

^#WHO-EM
^‡Withdrawn from market
Clinical trials:
- ^†Phase III
- ^§Never to phase III

This article is issued from Wikipedia - version of the Saturday, April 16, 2016. The text is available under the Creative Commons Attribution/Share Alike but additional terms may apply for the media files.